Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Patent
1996-09-06
1999-02-02
Low, Christopher F.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
4351723, 4353201, 435325, 435 691, 424 9321, C12N 1563, A01N 4304, A61K 3170
Patent
active
058665528
ABSTRACT:
A method of gene transfer involving administering a recombinant adeno-associated virus (AAV) bearing the desired gene into the muscle of the animal is described.
REFERENCES:
patent: 5139941 (1992-08-01), Muzyczka
patent: 5173414 (1992-12-01), Lebkowski
patent: 5252479 (1993-10-01), Srivastava
patent: 5354678 (1994-10-01), Lebkowski
patent: 5436146 (1995-07-01), Shenk
patent: 5474935 (1995-12-01), Chatterjee
patent: 5478745 (1995-12-01), Samulski
patent: 5753500 (1998-05-01), Shenk et al.
D. Coovert et al, "Gene Therapy for Muscle Diseases", Current Opinion in Neurology, 7:463-470 (1994).
R. Herzog et al, "Stable Gene Transfer and Expression of Human Blood Coagulation Factor IX After Intramuscular Injection of Recombinant Adeno-Associated Virus", Proc. Natl. Acad. Sci. USA, 94:5804-5809 (May 1997).
K. Fisher et al, "Recombinant Adeno-Associated Virus for Muscle Directed Gene Therapy", Nature Medicine, 3(3):306-312 (Mar. 1997).
P. Kessler et al, "Gene Delivery to Skeletal Muscle Results in Sustained Expression and Systemic Delivery of a Therapeutic Protein", Proc. Natl. Acad. Sci. USA, 93:14082-14087 (Nov. 1996).
D. Russell et al, "Adeno-Associated Virus Vectors Preferentially Transduce Cells in S Phase", Proc. Natl. Acad. Sci. USA, 91:8915-8919 (Sep. 1994).
J. Wolff et al, "Direct Gene Transfer into Mouse Muscle in Vivo", Science, 247:1465-1468 (Mar. 23, 1990).
H. Blau et al, "Localization of Muscle Gene Products in Nuclear Domains: Does this Constitute a Problem for Myoblast Therapy?", Adv. Exp. Med. Biol., 280:167-172 (1990).
N. Muzyczka, "Use of Adeno-Associated Virus as a General Transduction Vector for Mammalian Cells", Curr. Topics Microbiol. Immunol., 158:97-129 (1992).
R. Samulski et al, "Targeted Integration of Adeno-Associated Virus (AAV) into Human Chromosome 19", EMBO J., 10(12):3941-3950 (1991).
R. Kotin, "Prospects for the Use of Adeno-Associated Virus as a Vector for
R. Kotin et al, "Site-Specific Integration by Adeno-Associated Virus",
K. Fisher et al, "Transduction with Recombinant Adeno-Associated Virus for Gene Therapy is Limited by Leading-Strand Synthesis", J. Virol., 70(1):520-532 (Jan. 1996).
C. Hodgson, "Advances in Vector Systems for Gene Therapy", Exp. Opin. Ther. Patents, 5(5):459-468 (1995).
R. Samulski et al, "Helper-Free Stocks of Recombinant Adeno-Associated Viruses: Normal Integration Does not Require Viral Gene Expression", J. Virol., 63(9):3822-3828 (Sep. 1989).
M. Weitzman et al, "Recruitment of Wild-Type and Recombinant Adeno-Associated Virus into Adenovirus Replication Centers", J. Virol., 70(3):1845-1854 (Mar. 1996).
S. Goodman et al, "Recombinant Adeno-Associated Virus-Mediated Gene Transfer into Hematopoietic Progenitor Cells", Blood, 84(5):1492-1500 (Sep. 1994).
B. Yakobson et al, "Replication of Adeno-Associated Virus in Synchronized Cells without the Addition of a Helper Virus", J. Virol., 61(4):972-981 (Apr. 1987).
E. Kremer et al, "Adenovirus and Adeno-Associated Virus Mediated Gene Transfer", British Medical Bulletin, 51(1):31-44 (1995).
E. Raz et al, "Systemic Immunological Effects of Cytokine Genes Injected into Skeletal Muscle", Proc. Natl. Acad. Sci. USA, 90:4523-4527 (May 1993).
Xaio et al. J. of Virol. 70(11):8098-8108, Nov. 1996.
Xiaoet al. Adv. Drug Del. Rev. 12:201-215, 1993.
March et al. Clin. Res. 40(2) 358A, 1992.
Kaplitt et al Nature Genetics 8:148-153, Oct. 1994.
Einerhand et al. Gene Therapy 2(5):336-343, Jul. 1995.
Bartlett et al. Amer. J. Human Genetics 57.supp 4#A235, Oct. 1995.
LaFont Lancet. 346:1442-1443, 1995.
Orkin et al. Report and Recomendations . . . Gene Therapy. NIHPress. Dec. 7, 1995. pp. 1-40.
Miller et al. FASEB. vol. 9 :190-199, Feb. 1995.
Marshall. Science.269:1050-1055, Aug. 1995.
Culver et al. TIG. 10(5):174-178, May 1994.
Hodgson. Exp Opin Ther. Patents. 5(5):459-468, 1995.
Fisher Krishna J.
Wilson James M.
Low Christopher F.
Schmuck Jill D.
The Trustees of the University of Pennsylvania
LandOfFree
Method for expressing a gene in the absence of an immune respons does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for expressing a gene in the absence of an immune respons, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for expressing a gene in the absence of an immune respons will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1117533